Why the study?
Does exenatide prevent cardiac injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Does exenatide prevent cardiac injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Despite promising preclinical data, the clinical efficacy of GLP-1 receptor agonists like exenatide for cardioprotection during primary PCI in STEMI patients remains limited.
Limited evidence supports GLP-1 agonists for cardioprotection in STEMI PCI; leaves open efficacy in prospective trials.
The incretin hormone glucagon-like peptide-1 (GLP-1) (7-36)-based therapeutic strategies have been shown to have cardioprotective properties in animal models of ischemia and infarction due to promotion of myocardial glucose uptake and suppression of cardiac cell apoptosis. However, in patient with myocardial infarct, GLP-1 analogues' capacity to effectively protect the heart from dysfunction caused by supply ischemia during percutaneous coronary intervention is still limited. We herein review routine use of a GLP-1 receptor agonist, exenatide in patients with ST-segment elevation myocardial infarction at the time of primary percutaneous coronary intervention, highlight multiple pleotrophic effects and point out several important clinical issues that require consideration and exploration.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2013) conducted a review in ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). GLP-1 receptor agonist (exenatide) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: